Certolizumab Pegol
Brand name: Cimzia
Rank #187 of 500 drugs by total cost
$79.9M
Total Cost
11,784
Total Claims
$79.9M
Total Cost
629
Prescribers
$6,782
Cost per Claim
95
Beneficiaries
12,617
30-Day Fills
$127K
Avg Cost/Provider
19
Avg Claims/Provider
About Certolizumab Pegol
Certolizumab Pegol (sold as Cimzia) was prescribed 11,784 times by 629 Medicare Part D providers in 2023, costing the program $79.9M. At $6,782 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 184 | Mifepristone (Korlym) | $83.3M | 2,397 |
| 185 | Insulin Nph Hum/Reg Insulin Hm (Humulin 70-30) | $82.3M | 177,501 |
| 186 | Montelukast Sodium (Montelukast Sodium) | $81.3M | 5,086,706 |
| 187 | Certolizumab Pegol (Cimzia) | $79.9M | 11,784 |
| 188 | Celecoxib (Celecoxib) | $77.7M | 1,938,505 |
| 189 | Sod Phenylbutyrat/Taurursodiol (Relyvrio) | $77.0M | 6,152 |
| 190 | Pravastatin Sodium (Pravastatin Sodium) | $76.8M | 4,033,829 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology